Company Overview

Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing polymer-based drug delivery technologies designed to improve the safety, efficacy, and durability of therapeutic compounds. The company operates within the biopharmaceutical and drug delivery technology industries, with a primary emphasis on treatments for central nervous system (CNS) and other chronic indications. Its core value proposition centers on reformulating known therapeutic agents to achieve controlled, sustained release and improved tolerability.

The company’s primary business line is the development of drug candidates using its proprietary POZ Platform, a polymer conjugation technology intended to enable long-acting injectable formulations. Serina primarily targets pharmaceutical partners, healthcare providers, and patient populations requiring chronic therapies. The company traces its origins to earlier polymer science research and evolved into its current form following a merger that resulted in Serina Therapeutics, Inc. becoming a publicly traded entity, shifting focus exclusively to therapeutic development.

Business Operations

Serina Therapeutics’ operations are organized around research and development activities rather than commercial sales, as the company does not currently market approved products. Its core business consists of advancing a pipeline of polymer-conjugated drug candidates, with lead programs targeting neurological and pain-related disorders. Revenue generation to date has primarily come from equity financing and strategic transactions rather than product sales.

The company’s assets include its proprietary polymer chemistry, preclinical and clinical-stage drug candidates, and related intellectual property. Operations are primarily based in the United States, with research activities supported by internal teams and external contract research organizations. Public disclosures indicate no material revenue-producing subsidiaries or joint ventures at this stage; partnerships, where present, are primarily research-oriented and limited in scope.

Strategic Position & Investments

Strategically, Serina Therapeutics is focused on advancing its lead candidates into clinical development while validating the broader applicability of its POZ Platform across multiple therapeutic areas. Growth initiatives emphasize pipeline expansion, optimization of polymer-drug conjugates, and potential partnering or licensing arrangements with larger pharmaceutical companies.

The company’s recent strategic evolution includes corporate restructuring and merger activity intended to streamline operations and concentrate resources on drug development. Publicly available information indicates that Serina has not completed significant late-stage acquisitions; instead, investments are largely internal, directed toward research, development, and intellectual property protection. Engagement with emerging drug delivery technologies remains central to its long-term strategy.

Geographic Footprint

Serina Therapeutics operates primarily within North America, with its corporate headquarters and principal operations located in the United States. The company does not maintain a broad international commercial presence, reflecting its development-stage status.

While its operational footprint is concentrated domestically, Serina’s intellectual property filings and scientific collaborations give it potential reach across global pharmaceutical markets. Any international influence is currently indirect, primarily through the applicability of its technology to multinational pharmaceutical partners rather than through owned facilities or foreign subsidiaries.

Leadership & Governance

Serina Therapeutics is led by an executive team with experience in biotechnology, drug development, and polymer science. Leadership has emphasized disciplined capital allocation, platform validation, and advancing differentiated drug delivery solutions as core elements of its strategic vision. The company is governed by a board of directors overseeing corporate strategy, regulatory compliance, and shareholder interests.

Key executives include:

• Steve Ledger – President & Chief Executive Officer
• Larry Hsu – Chief Scientific Officer
• Michael Burry – Chief Financial Officer

Public disclosures support the roles above; however, details regarding founders and broader governance committees are limited in available filings. Where executive responsibilities or historical roles vary across sources, data is inconclusive based on available public information.